Metformin with chemotherapy or immunotherapy for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests if adding metformin, a common diabetes drug, to standard chemotherapy or immunotherapy can help treat advanced solid tumors. It may be an option for people who are already eligible for chemo or immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced solid tumor that can be treated with chemotherapy or immunotherapy.
- You are at least 18 years old.
- Your tumors can be measured on scans.
- Your blood counts, kidney, and liver function are within certain limits.
- You have a life expectancy of at least 12 weeks.
- You are not currently taking metformin and have not taken it in the last 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two investigational drugs (Simmitinib and SG001) in people with advanced solid tumors that have not responded to standard treatment. The goal is to see if this combination can shrink tumors or slow their growth, and to find the best dose for further studies.
This trial tests whether adding metformin (a diabetes drug) to standard chemotherapy (FOLFIRI) and targeted therapy can help people with metastatic colorectal cancer live longer or respond better to treatment.
This trial tests canagliflozin, a diabetes drug, combined with immunotherapy for people with advanced solid tumors. It may help if you have type 2 diabetes or are at risk, but you don't need diabetes to join.
This trial tests adding metformin, a common diabetes drug, to the usual first cancer treatment for advanced soft tissue sarcoma. It may help the standard therapy work better.
This Phase 3 study tests whether adding metformin to standard targeted medicines (tyrosine kinase inhibitors) helps people with EGFR-mutated non-small cell lung cancer. It’s meant for people who haven’t already had EGFR-targeted treatment and who have healthy enough labs and organs to safely take the study medicines.
This study tests if metformin, a common diabetes medicine, can help reduce insulin resistance in women who finished chemotherapy for early-stage breast cancer. It aims to improve long-term health and prevent future problems.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.